Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: A phase III overview

Expert Review of Anticancer Therapy

Volumn 7, Issue 9, 2007, Pages 1193-1202

  Hutson, Thomas E ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neoplasm; Renal cell carcinoma; Review; Safety

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; GEFITINIB; INTERFERON; INTERLEUKIN 2; LOPERAMIDE; OPIATE; PLACEBO; RECOMBINANT INTERLEUKIN 2; SALICYLIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THYROID HORMONE; UREA;

ADVANCED CANCER; ALDOSTERONE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HORMONE SUBSTITUTION; HUMAN; HYPERKERATOSIS; HYPERTENSION; HYPERURICEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; LONG TERM CARE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MONOTHERAPY; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PLASMA RENIN ACTIVITY; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III; HUMANS; KIDNEY NEOPLASMS; PYRIDINES;

EID: 34948881749     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.9.1193     Document Type: Review

References (44)

1. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272-1278 (1998).
2. Negrier S, Maral J, Drevon M et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J. Sci. Am. 6(Suppl. 1), S93-S98 (2000).
3. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J. Clin. Oncol. 23, LBA4511 (2005) (Meeting Abstract).
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Fngl. J. Med. 356, 115-124 (2007).
5. Escudier B, Szczylik C, Demkow T et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naive patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 24, 4501 (2006) (Meeting Abstract).
6. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98, 326-334 (2006).
7. Levy AP, Pauloski N, Braun D et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multikinase inhibitor sorafenib (BAY 43-9006). Proc. Am. Assoc. Cancer Res. 47, 213 (2006).
8. Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10, 191-197 (2005).
9. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
10. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66, 1611-1619 (2006).
11. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227 (2005).
12. Yu C, Bruzek LM, Meng XW et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869 (2005).
13. Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur. J. Cancer 42, 548-556 (2006).
14. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
15. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
16. Eisen T, Bukowski RM, Staehler M et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J. Clin. Oncol. 24, 4524 (2006) (Meeting Abstract).
17. Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol. 25, 5023 (2007) (Meeting Abstract).
18. Steinbild S, Mross K, Morant D et al. Phase II study of sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research-EWIV (CESAR). J. Clin. Oncol. 24, 3094 (2006) (Meeting Abstract).
19. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am. J. Clin. Dermatol. 1, 225-234 (2000).
20. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 6, 491-500 (2005).
21. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24, 1363-1369 (2006).
22. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. 24, 1329-1331 (2006).
23. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17, 23-28 (2003).
24. Schoeffski P, Wolter P, Himpe U et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J. Clin. Oncol. 24, 3092 (2006) (Meeting Abstract).
25. Shaheen PE, Tamaskar IR, Salas RN et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J. Clin. Oncol. 24, 4605 (2006) (Meeting Abstract).
26. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99, 81-83 (2007).
27. Tamaskar IR, Unnithan J, Garcia JA et al. Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. J. Clin. Oncol. 25, 5048 (2007) (Meeting Abstract).
28. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
29. Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/ interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J. Clin. Oncol. 25, 3 (2007) (Meeting Abstract).
30. Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. 24, LBA4 (2006) (Meeting Abstract).
31. Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J. Clin. Oncol. 25, 5033 (2007) (Meeting Abstract).
32. Szczylik C, Dmkow T, Staehler M et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol. 25, 5025 (2007) (Meeting Abstract).
33. Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin. Genitourin. Cancer 4, 181-186 (2005).
34. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
35. Azad NS, Posadas EM, Kwitkowski VE et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J. Clin. Oncol. 24, 3004 (2006) (Meeting Abstract).
36. Flaherty KT, Brose M, Schuchter L et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J. Clin. Oncol. 22, 7507 (2004) (Abstract).
37. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33, 392-406 (2006).
38. Kupsch P, Henning BF, Passarge K et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5, 188-196 (2005).
39. Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J. Clin. Oncol. 24, 4525 (2006) (Meeting Abstract).
40. Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res. 13, 1801-1809 (2007).
41. Patel PH, Kondagunta GV, Redman BG et al. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25, 5097 (2007) (Meeting Abstract).
42. Knox JJ, Figlin RA, Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J. Clin. Oncol. 25, 5011 (2007) (Meeting Abstract).
43. Ryan CW, Bukowski RM, Figlin RA et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients (pts). J. Clin. Oncol. 25, 5096 (2007) (Meeting Abstract).
44. Stadler WM, Figlin RA, Ernstoff MS et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J. Clin. Oncol. 25, 5036 (2007) (Meeting Abstract).